

Edward V Nunes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3379803/publications.pdf>

Version: 2024-02-01

126
papers

6,238
citations

87723

38
h-index

74018

75
g-index

132
all docs

132
docs citations

132
times ranked

4933
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2018, 391, 309-318.	6.3	502
2	Treatment of Depression in Patients With Alcohol or Other Drug Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1887.	3.8	474
3	Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. <i>Lancet, The</i> , 2011, 377, 1506-1513.	6.3	451
4	Cognitive deficits predict low treatment retention in cocaine dependent patients. <i>Drug and Alcohol Dependence</i> , 2006, 81, 313-322.	1.6	349
5	Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. <i>New England Journal of Medicine</i> , 2016, 374, 1232-1242.	13.9	255
6	Development of a Cascade of Care for responding to the opioid epidemic. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 1-10.	1.1	212
7	Internet-Delivered Treatment for Substance Abuse: A Multisite Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2014, 171, 683-690.	4.0	203
8	The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): Procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample. <i>Drug and Alcohol Dependence</i> , 2015, 148, 40-46.	1.6	192
9	Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. <i>JAMA Internal Medicine</i> , 2018, 178, 764.	2.6	148
10	Bupropion and Naltrexone in Methamphetamine Use Disorder. <i>New England Journal of Medicine</i> , 2021, 384, 140-153.	13.9	139
11	Treatment of depression in patients with opiate dependence. <i>Biological Psychiatry</i> , 2004, 56, 793-802.	0.7	138
12	Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder. <i>JAMA Psychiatry</i> , 2015, 72, 593.	6.0	131
13	Developing an opioid use disorder treatment cascade: A review of quality measures. <i>Journal of Substance Abuse Treatment</i> , 2018, 91, 57-68.	1.5	114
14	Cognition, commitment language, and behavioral change among cocaine-dependent patients.. <i>Psychology of Addictive Behaviors</i> , 2008, 22, 557-562.	1.4	98
15	Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. <i>Addiction</i> , 2013, 108, 1628-1637.	1.7	98
16	Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. <i>World Psychiatry</i> , 2021, 20, 397-404.	4.8	97
17	A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2019, 176, 923-930.	4.0	94
18	Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population. <i>Drug and Alcohol Dependence</i> , 2015, 152, 246-256.	1.6	92

#	ARTICLE	IF	CITATIONS
19	Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 49-55.	1.5	86
20	A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. <i>American Journal of Psychiatry</i> , 2020, 177, 125-133.	4.0	85
21	Behavioral Therapy to Augment Oral Naltrexone for Opioid Dependence: A Ceiling on Effectiveness?. <i>American Journal of Drug and Alcohol Abuse</i> , 2006, 32, 503-517.	1.1	84
22	Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. <i>Drug and Alcohol Dependence</i> , 2016, 159, 53-60.	1.6	79
23	The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. <i>Drug and Alcohol Dependence</i> , 2015, 154, 38-45.	1.6	78
24	Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine. <i>American Journal of Psychiatry</i> , 2017, 174, 459-467.	4.0	76
25	Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. <i>Addiction</i> , 2019, 114, 1416-1426.	1.7	75
26	Self-Report After Randomly Assigned Supervision Does not Predict Ability to Practice Motivational Interviewing. <i>Journal of Substance Abuse Treatment</i> , 2015, 57, 96-101.	1.5	71
27	Independent Versus Substance-Induced Major Depressive Disorder in Substance-Dependent Patients. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1561-1567.	1.1	66
28	Measures of Attentional Bias and Relational Responding Are Associated with Behavioral Treatment Outcome for Cocaine Dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 146-154.	1.1	62
29	A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder. <i>American Journal of Psychiatry</i> , 2019, 176, 129-137.	4.0	62
30	Comorbidity of substance use with depression and other mental disorders: from Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) to DSM-V. <i>Addiction</i> , 2006, 101, 89-96.	1.7	58
31	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1075-1082.	1.1	53
32	Risk/Protective Factors Among Addicted Mothers' Offspring: A Replication Study. <i>American Journal of Drug and Alcohol Abuse</i> , 1999, 25, 661-679.	1.1	50
33	Venlafaxine Treatment of Cocaine Abusers with Depressive Disorders. <i>American Journal of Drug and Alcohol Abuse</i> , 2000, 26, 25-31.	1.1	50
34	Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: An example from the NIDA Clinical Trials Network. <i>Contemporary Clinical Trials</i> , 2012, 33, 386-395.	0.8	50
35	Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. <i>Annals of Internal Medicine</i> , 2019, 170, 90.	2.0	50
36	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	1.6	50

#	ARTICLE	IF	CITATIONS
37	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , 2016, 50, 253-264.	0.8	49
38	The Effect of Sertraline on Methadone Plasma Levels in Methadone-Maintenance Patients. <i>American Journal on Addictions</i> , 2000, 9, 63-69.	1.3	46
39	Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2016, 161, 119-126.	1.6	45
40	Baseline Matters: The Importance of Covariation for Baseline Severity in the Analysis of Clinical Trials. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 446-452.	1.1	41
41	Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial. <i>American Journal on Addictions</i> , 2018, 27, 465-470.	1.3	40
42	Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX). <i>Journal of Addiction Medicine</i> , 2015, 9, 238-243.	1.4	39
43	The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 4-11.	1.5	39
44	Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?. <i>Journal of Substance Abuse Treatment</i> , 2021, 122, 108196.	1.5	39
45	Epidemiology, Pathophysiology and Treatment of Pathological Gambling. <i>CNS Drugs</i> , 2000, 13, 397-407.	2.7	38
46	Naltrexone treatment for opioid dependence: Does its effectiveness depend on testing the blockade?. <i>Drug and Alcohol Dependence</i> , 2013, 133, 80-85.	1.6	37
47	A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 546-552.	1.5	37
48	Acceptability of a Web-Based Community Reinforcement Approach for Substance Use Disorders with Treatment-Seeking American Indians/Alaska Natives. <i>Community Mental Health Journal</i> , 2015, 51, 393-403.	1.1	36
49	Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107700.	1.6	33
50	The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 22-26.	1.1	31
51	COVID-19, mental health, and opioid use disorder: Old and new public health crises intertwine.. <i>Psychological Trauma: Theory, Research, Practice, and Policy</i> , 2020, 12, S111-S112.	1.4	30
52	Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence. <i>Contemporary Clinical Trials</i> , 2016, 51, 34-43.	0.8	28
53	Pergolide Mesylate for Cocaine Abuse: A Controlled Preliminary Trial. <i>American Journal on Addictions</i> , 1999, 8, 120-127.	1.3	25
54	Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S97-S112.	1.5	24

#	ARTICLE	IF	CITATIONS
55	Utility of lead-in period in cocaine dependence pharmacotherapy trials. <i>Drug and Alcohol Dependence</i> , 2005, 77, 7-11.	1.6	23
56	Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. <i>Drug and Alcohol Dependence</i> , 2015, 147, 122-129.	1.6	22
57	Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. <i>Substance Abuse</i> , 2021, 42, 245-254.	1.1	22
58	How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis. <i>Drug and Alcohol Dependence</i> , 2018, 188, 135-140.	1.6	21
59	Evaluation and Treatment of Mood and Anxiety Disorders in Opioid-Dependent Patients. <i>Journal of Psychoactive Drugs</i> , 1994, 26, 147-153.	1.0	20
60	Web-based treatment for substance use disorders: Differential effects by primary substance. <i>Addictive Behaviors</i> , 2015, 45, 191-194.	1.7	20
61	Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders. <i>American Journal on Addictions</i> , 2017, 26, 319-325.	1.3	20
62	Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder. <i>Journal of Adolescent Health</i> , 2020, 67, 778-785.	1.2	20
63	Cigarette Smoking During Substance Use Disorder Treatment: Secondary Outcomes from a National Drug Abuse Treatment Clinical Trials Network study. <i>Journal of Substance Abuse Treatment</i> , 2015, 53, 39-46.	1.5	19
64	Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 61-65.	1.5	19
65	Addiction Psychiatry and Addiction Medicine: The Evolution of Addiction Physician Specialists. <i>American Journal on Addictions</i> , 2020, 29, 390-400.	1.3	18
66	Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. <i>American Journal of Psychiatry</i> , 2021, 178, 660-671.	4.0	18
67	Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , 2020, 115, 239-246.	1.7	17
68	Quetiapine treatment for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108366.	1.6	16
69	Workshop on Implementation Science and Digital Therapeutics for Behavioral Health. <i>JMIR Mental Health</i> , 2021, 8, e17662.	1.7	15
70	Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?. <i>Drug and Alcohol Dependence</i> , 2014, 144, 42-46.	1.6	14
71	Multimodal predictive modeling of individual treatment outcome in cocaine dependence with combined neuroimaging and behavioral predictors. <i>Drug and Alcohol Dependence</i> , 2014, 143, 29-35.	1.6	14
72	The "Women and Trauma" study and its national impact on advancing trauma specific approaches in community substance use treatment and research. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 12-17.	1.5	13

#	ARTICLE	IF	CITATIONS
73	Dissociative Identity Disorder and Substance Abuse: The Forgotten Relationship. <i>Journal of Psychoactive Drugs</i> , 1999, 31, 71-83.	1.0	12
74	Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108447.	1.5	12
75	Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. <i>Addictive Behaviors</i> , 2017, 65, 74-80.	1.7	11
76	Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108221.	1.6	11
77	Patient- and Provider-Reported Experiences of a Mobile Novel Digital Therapeutic in People With Opioid Use Disorder (reSET-O): Feasibility and Acceptability Study. <i>JMIR Formative Research</i> , 2022, 6, e33073.	0.7	11
78	Gabapentin. <i>JAMA Internal Medicine</i> , 2014, 174, 78.	2.6	10
79	New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders. <i>Current Psychiatry Reports</i> , 2016, 18, 64.	2.1	10
80	Factors Influencing Buprenorphine Prescribing among Physicians in New York State. <i>Journal of Addiction</i> , 2019, 2019, 1-5.	0.9	10
81	Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual. <i>Journal of Addiction Medicine</i> , 2020, 14, 331-336.	1.4	10
82	Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 66-69.	1.5	9
83	Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. <i>Drug and Alcohol Dependence</i> , 2019, 194, 482-486.	1.6	9
84	<p>Medical Student Attitudes Toward Substance Use Disorders Before and After a Skills-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Curriculum</p>. <i>Advances in Medical Education and Practice</i> , 2020, Volume 11, 455-461.	0.7	9
85	Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. <i>American Journal of Managed Care</i> , 2018, 24, 526-531.	0.8	9
86	Workshop on the Development and Evaluation of Digital Therapeutics for Health Behavior Change: Science, Methods, and Projects. <i>JMIR Mental Health</i> , 2020, 7, e16751.	1.7	8
87	Rationale for Using Exercise in the Treatment of Stimulant Use Disorders. <i>Journal of Global Drug Policy and Practice</i> , 2012, 6, .	0.0	8
88	Derived relations moderate the association between changes in the strength of commitment language and cocaine treatment response.. <i>Experimental and Clinical Psychopharmacology</i> , 2016, 24, 77-89.	1.3	7
89	Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure. <i>Journal of Substance Abuse Treatment</i> , 2021, 124, 108292.	1.5	7
90	Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108585.	1.5	7

#	ARTICLE	IF	CITATIONS
91	Toward National Estimates of Effectiveness of Treatment for Substance Use. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e64-e70.	1.1	7
92	Stepped-wedge randomized controlled trial of a novel opioid court to improve identification of need and linkage to medications for opioid use disorder treatment for court-involved adults. <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108277.	1.5	6
93	Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder. <i>Journal of Substance Abuse Treatment</i> , 2015, 59, 104-108.	1.5	5
94	Sociodemographic and Substance Use Disorder Determinants of HIV Sexual Risk Behavior in Men and Women in Outpatient Drug Treatment in the NIDA National Drug Abuse Treatment Clinical Trials Network. <i>Substance Use and Misuse</i> , 2017, 52, 858-865.	0.7	5
95	Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults. <i>Addictive Behaviors</i> , 2020, 110, 106514.	1.7	5
96	COVID-19 related substance use services policy changes: Policymaker perspectives on policy development & implementation. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108550.	1.5	5
97	Safety and Efficacy of a Digital Therapeutic for Substance use Disorder: Secondary Analysis of Data from a NIDA Clinical Trials Network Study. <i>Substance Abuse</i> , 2022, 43, 937-942.	1.1	5
98	Bromocriptine Treatment for Cocaine Addiction. <i>American Journal on Addictions</i> , 1993, 2, 169-172.	1.3	4
99	Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables. <i>Addiction</i> , 2021, 116, 2094-2103.	1.7	4
100	Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial. <i>American Journal on Addictions</i> , 2021, 30, 433-444.	1.3	4
101	Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. <i>Addiction</i> , 2022, 117, 637-645.	1.7	4
102	Optimizing opioid use disorder treatment with naltrexone or buprenorphine. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109031.	1.6	4
103	The Design and Analysis of Multisite Effectiveness Trials: A Decade of Progress in the National Drug Abuse Clinical Trials Network. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 269-272.	1.1	3
104	Effects of levodopa-carbidopa-entacapone and smoked cocaine on facial affect recognition in cocaine smokers. <i>Journal of Psychopharmacology</i> , 2016, 30, 370-377.	2.0	3
105	Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 653-659.	1.1	3
106	Medication Treatments for Opioid Use Disorder: What Is the Impact on Mood and Mood Disorders?. <i>Current Addiction Reports</i> , 2018, 5, 303-311.	1.6	3
107	Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD. <i>American Journal on Addictions</i> , 2019, 28, 497-502.	1.3	3
108	Commentary on Stein et al . (2020): Whither detoxification in the face of the opioid epidemic?. <i>Addiction</i> , 2020, 115, 95-96.	1.7	3

#	ARTICLE	IF	CITATIONS
109	Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 761-768.	1.1	3
110	Exploring gender differences among treatment-seekers who use opioids versus alcohol and other drugs. <i>Women and Health</i> , 2020, 60, 821-838.	0.4	3
111	Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 6.	1.2	3
112	Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. <i>Drug and Alcohol Dependence</i> , 2022, 233, 109343.	1.6	3
113	Lithium Treatment of Aggressive Behavior in Depressed, Drug-Dependent Patients. <i>American Journal on Addictions</i> , 1996, 5, 87-90.	1.3	2
114	Treatment of Comorbid Affective and Substance Use Disorders: Therapeutic Potential of Anticonvulsants. <i>American Journal on Addictions</i> , 1998, 7, 210-220.	1.3	2
115	Physical health problems in depressed and nondepressed children and adolescents of parents with opiate dependence. , 1999, 9, 61-69.		2
116	Commentary on Zhou et al. (2015): Treating psychiatric comorbidity in adolescents—an important problem. <i>Addiction</i> , 2015, 110, 49-50.	1.7	2
117	Psychological Symptoms and Outcomes in Adults Receiving Community-based Treatment for Substance Use Disorders. <i>Substance Use and Misuse</i> , 2021, 56, 1258-1265.	0.7	2
118	Group Psychotherapy for Treatment Refractory Methadone Maintenance Patients. <i>Journal of Maintenance in the Addictions</i> , 1997, 1, 103-113.	0.1	2
119	Clinical and translational research: introduction to the special issue. <i>Experimental and Clinical Psychopharmacology</i> , 2002, 10, 155-8.	1.3	2
120	Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 31-33.	1.5	1
121	Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders. <i>Journal of Substance Abuse Treatment</i> , 2019, 105, 64-70.	1.5	1
122	Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. <i>Addiction</i> , 2021, 116, 3444-3453.	1.7	1
123	Buprenorphine in the real world: coming to terms with misuse and diversion. <i>American Journal of Drug and Alcohol Abuse</i> , 2018, 44, 576-577.	1.1	0
124	Responding to the Opioid Crisis: Lessons From a Review of Casualties. <i>Psychiatric Services</i> , 2019, 70, 89-89.	1.1	0
125	Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. <i>Addiction</i> , 2020, 115, 2188-2190.	1.7	0
126	Support for COVID-19-Related Substance Use Services Policy Changes: a New York State-Wide Survey. <i>Journal of Behavioral Health Services and Research</i> , 2022, , 1.	0.6	0